Evofem Biosciences (EVFM) Stock Price & Analysis

1,208 Followers

EVFM Stock Chart & Stats

$0.01$0.00(5.83%)

At close: Nov 02 10:30 AM EST

Day’s Range: $0.01 - $0.01
52-Week Range: $0.01 - $0.02
Previous Close: $0.01
Volume: N/A
Average Volume (3M): 491.38K
Market Cap: $808.43K
Enterprise Value: $60.16M
Total Cash (Recent Filing): $285.00K
Total Debt (Recent Filing): $68.50M
Price to Earnings (P/E): ―
Beta: 0.18
Next Earnings: Nov 12, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margin

A gross margin of about 71% indicates that Phexxi generates substantial value after direct product costs. If maintained, this provides a foundation for covering operating expenses, supporting commercialization investments, and improving earnings potential as revenue scale and manufacturing economics develop.

Expanded Phexxi Manufacturing Capacity

Adding Zhaoke as a second Phexxi producer broadens the manufacturing footprint and reduces reliance on the existing source. Subject to regulatory approval, greater capacity and lower unit costs could support U.S. and international demand while strengthening the product’s commercial economics.

Cash-burn Improvement

Although cash flow remains below breakeven, the sharp reduction in operating and free-cash-flow losses versus 2021–2023 shows meaningful progress in cash management. Continued improvement could reduce financing dependence and move the business closer to becoming self-funding over time.

Bears Say

Declining Revenue

A revenue decline of roughly 23.8% signals weakening recent commercial performance and makes it harder to absorb the company’s operating cost base. Persistent contraction could limit investment capacity, weaken negotiating leverage, and delay the benefits expected from expanded Phexxi production.

Negative Equity And Elevated Leverage

Persistently negative equity combined with sizable debt and a comparatively small asset base materially restricts financial flexibility. This structure increases refinancing and solvency risk, limits the ability to fund growth internally, and leaves less capacity to absorb operating setbacks.

Severe Profitability Deterioration

The shift from a small 2025 profit to approximately a -100% TTM net margin shows that current revenue is not covering the broader operating model. Negative operating earnings may prolong cash needs, constrain reinvestment, and prevent the strong gross margin from translating into sustainable profitability.

Evofem Biosciences News

Evofem amends key convertible note financing terms

Evofem Biosciences ( ($EVFM) ) has provided an update. On October 9, 2026, Evofem Biosciences, Inc. and Adjuvant Global Health Technology Fund entered into a fifth amendment to their October

2w ago8K EVFM

Evofem Expands PHEXX Manufacturing Capacity for Global Growth

Evofem Biosciences ( ($EVFM) ) has issued an update. On September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou

1M ago8K EVFM

Evofem reports shipment of 500,000th box of PHEXX

Evofem (EVFM) Biosciences announced the shipment of its 500,000th box of PHEXX, the first and only FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel. Published first on TheFly – the ultimate

3M agoEVFM

Evofem Biosciences Updates Investors via New Presentation

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences, Inc., a biotechnology company focused on women’s health, periodically shares corporate slide presentations with the investment community

3M ago8K EVFM

Evofem Biosciences Enters New Subordinated Debt Agreement

Evofem Biosciences ( ($EVFM) ) has issued an update. On July 8, 2026, Evofem Biosciences entered into a subordinated promissory note with HUB Cyber Security, Ltd. for $706,304, carrying 12%

3M ago8K EVFM

Evofem reports Q1 EPS (4c) vs. 0c last year

Reports Q1 revenue $0.9M vs. $0.8M last year. “Evofem (EVFM) continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra

5M agoEVFM

Evofem Biosciences Secures Solosec Distribution Deal in Africa

An announcement from Evofem Biosciences ( ($EVFM) ) is now available. On April 24, 2026, Evofem Biosciences, Inc. entered into an exclusive five-year agreement with Clovis Davis Pharmaceuticals, LLC to

6M ago8K EVFM

Evofem enters exclusive distribution agreement with Clovis Davis for SOLOSEC

Evofem (EVFM) Biosciences entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC 2g oral granules in sub-Saharan Africa. SOLOSEC is approved by the U.S. Food and

6M agoEVFM

Evofem Biosciences Amends Convertible Note Financing Terms

Evofem Biosciences ( ($EVFM) ) has provided an announcement. On April 10, 2026, Evofem Biosciences, Inc. and funds affiliated with Adjuvant Global Health Technology Fund entered into a fourth amendment

6M ago8K EVFM

Evofem Biosciences Reports First Year of Operating Profit

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). On March 11, 2026, Evofem Biosciences reported financial results for the fourth quarter and full year 2025, marking its

7M ago8K EVFM

Evofem Biosciences posts updated corporate investor presentation

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences, Inc. reported that it periodically shares slide presentations with the investment community at industry and other conferences

9M ago8K EVFM

Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals

The latest update is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences held its Annual Meeting on November 26, 2025, where various proposals were voted on by the stockholders.

11M ago8K EVFM

Evofem Biosciences Reports Q3 2025 Earnings

Evofem Biosciences, Inc. ( ($EVFM) ) has released its Q3 earnings. Here is a breakdown of the information Evofem Biosciences, Inc. presented to its investors. Evofem Biosciences, Inc. is a

11M agoEVFM

Evofem says FDA Orange Book lists patent for Solosec treatment

Evofem (EVFM) Biosciences announced that a newly-issued U.S. patent which covers SOLOSEC 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and

1y agoEVFM

EVFM FAQ

What was Evofem Biosciences’s price range in the past 12 months?

Evofem Biosciences lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.

What is Evofem Biosciences’s market cap?

Evofem Biosciences’s market cap is $808.43K.

When is Evofem Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Evofem Biosciences’s earnings last quarter?

Evofem Biosciences released its earnings results on Aug 19, 2026. The company reported -$0.081 earnings per share for the quarter.

Is Evofem Biosciences overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Evofem Biosciences pay dividends?

Evofem Biosciences does not currently pay dividends.

What is Evofem Biosciences’s EPS estimate?

Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Evofem Biosciences have?

Evofem Biosciences has 132,530,080 shares outstanding.

What happened to Evofem Biosciences’s price movement after its last earnings report?

Evofem Biosciences reported an EPS of -$0.081 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Evofem Biosciences?

Currently, no hedge funds are holding shares in EVFM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description